DE69228700D1 - Verwendung von Decorin oder Biglycan zur Herstellung eines Medikaments für die Behandlung von Diabetes-bedingter Zustände - Google Patents

Verwendung von Decorin oder Biglycan zur Herstellung eines Medikaments für die Behandlung von Diabetes-bedingter Zustände

Info

Publication number
DE69228700D1
DE69228700D1 DE69228700T DE69228700T DE69228700D1 DE 69228700 D1 DE69228700 D1 DE 69228700D1 DE 69228700 T DE69228700 T DE 69228700T DE 69228700 T DE69228700 T DE 69228700T DE 69228700 D1 DE69228700 D1 DE 69228700D1
Authority
DE
Germany
Prior art keywords
fibrosis
diabetes
growth factor
biglycan
decorin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69228700T
Other languages
English (en)
Other versions
DE69228700T2 (de
Inventor
Erkki Ruoslahti
Wayne Border
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Burnham Prebys Medical Discovery Institute filed Critical Sanford Burnham Prebys Medical Discovery Institute
Application granted granted Critical
Publication of DE69228700D1 publication Critical patent/DE69228700D1/de
Publication of DE69228700T2 publication Critical patent/DE69228700T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69228700T 1991-12-04 1992-12-04 Verwendung von Decorin oder Biglycan zur Herstellung eines Medikaments für die Behandlung von Diabetes-bedingter Zustände Expired - Lifetime DE69228700T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80328591A 1991-12-04 1991-12-04
PCT/US1992/010550 WO1993010808A1 (en) 1991-12-04 1992-12-04 INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX

Publications (2)

Publication Number Publication Date
DE69228700D1 true DE69228700D1 (de) 1999-04-22
DE69228700T2 DE69228700T2 (de) 1999-09-09

Family

ID=25186123

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69228700T Expired - Lifetime DE69228700T2 (de) 1991-12-04 1992-12-04 Verwendung von Decorin oder Biglycan zur Herstellung eines Medikaments für die Behandlung von Diabetes-bedingter Zustände

Country Status (10)

Country Link
EP (1) EP0616536B1 (de)
JP (2) JP3854307B2 (de)
AT (1) ATE177644T1 (de)
AU (2) AU670770B2 (de)
CA (1) CA2124591A1 (de)
DE (1) DE69228700T2 (de)
DK (1) DK0616536T3 (de)
FI (1) FI942622A (de)
NO (1) NO942072L (de)
WO (1) WO1993010808A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5453492A (en) * 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
WO1995013827A1 (en) * 1993-11-19 1995-05-26 The University Of Sydney A method for preventing or controlling cataract
DE69535976D1 (de) * 1994-03-29 2009-08-13 Renovo Ltd Heilung von Wunden oder fibrotischen Krankheiten unter Verwendung von wenigstens einem Agens gegen einen Wachstumsfaktor
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
DE19613691A1 (de) * 1996-04-05 1997-10-09 Boehringer Ingelheim Int Arzneimittel für die Behandlung von Tumorerkrankungen
US6316258B1 (en) * 1998-01-09 2001-11-13 University Of Utah Methods for preventing and treating fibrotic diseases resulting from accumulation of excess extracellular matrix induced by TGFβ using renin inhibitors
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
AU2008200019B2 (en) * 1999-01-05 2009-10-08 American National Red Cross Methods for treating conditions associated with the accumulation of excess extracellular matrix
CA2358400C (en) * 1999-01-05 2012-05-15 Nancy A. Noble Methods for treating conditions associated with the accumulation of excess extracellular matrix
US6864236B1 (en) * 1999-11-18 2005-03-08 Brown University Research Foundation Biglycan and related therapeutics and methods of use
US7612038B2 (en) 1999-11-18 2009-11-03 Brown University Biglycan and related therapeutics and methods of use
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
EP1423133B1 (de) 2001-08-15 2009-01-14 Brown University Research Foundation Behandlung von muskeldystrophien und verwandter erkrankungen
US20030180301A1 (en) * 2002-01-22 2003-09-25 Shaf Keshavjee Use of TGF-beta antagonists to treat or to prevent chronic transplant rejection
WO2004075917A1 (ja) * 2003-02-28 2004-09-10 Toudai Tlo, Ltd. 器官または組織の線維化抑制剤
ES2526705T3 (es) 2005-10-25 2015-01-14 The Johns Hopkins University Métodos y composiciones para el tratamiento de síndrome de Marfan y trastornos asociados
US8454952B2 (en) 2006-03-13 2013-06-04 The Johns Hopkins University Augmentation of endothelial thromboresistance
EP1983345A1 (de) * 2007-04-17 2008-10-22 Roche Diagnostics GmbH Mittel und Verfahren zur Bewertung des Risikos eines Herzeingriffs bei Patienten, die an einer auf GDF-15 basierenden stabilen Erkrankung der Herzkorona leiden
EP2835053B1 (de) 2010-03-12 2016-04-27 Genzyme Corporation Kombinationstherapie zur Behandlung von Brustkrebs
EP2571514B1 (de) 2010-05-17 2018-07-18 Brown University Biglycan-mutanten sowie entsprechende therapiemittel und verwendungsverfahren dafür
CA2823154A1 (en) 2010-12-27 2012-07-05 Lsip, Llc Ips cells and method for generating same
AU2011352228B2 (en) 2010-12-27 2015-12-03 Brown University Therapeutic and diagnostic methods involving biglycan and utrophin
KR102577578B1 (ko) 2011-06-03 2023-09-11 조마 테크놀로지 리미티드 Tgf-베타에 특이적인 항체
US20150044178A1 (en) 2011-12-28 2015-02-12 Kyoto Prefectural Public University Corporation Normalization of culture of corneal endothelial cells
JPWO2015064768A1 (ja) 2013-10-31 2017-03-09 京都府公立大学法人 角膜内皮の小胞体細胞死関連疾患治療薬
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
WO2017223268A1 (en) * 2016-06-22 2017-12-28 Yale University COMPOSITIONS AND METHODS OF RESENSITIZING CELLS TO BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN INHIBITORS (BETi)
JP7109039B2 (ja) 2016-07-07 2022-07-29 国立大学法人千葉大学 抗線維症剤およびリン酸化Ｓｍａｄ核内移行阻害剤
KR102141125B1 (ko) * 2018-01-22 2020-08-05 고려대학교 산학협력단 비글리칸을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물
WO2019143219A1 (ko) * 2018-01-22 2019-07-25 고려대학교 산학협력단 비글리칸을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물
KR20200120878A (ko) * 2019-04-11 2020-10-22 고려대학교 산학협력단 비글리칸을 유효성분으로 함유하는 비만의 예방 또는 치료용 약학 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0775742A3 (de) * 1989-09-29 1998-01-14 La Jolla Cancer Research Foundation Inhibierung von TGF-beta zur Verhinderung von extrazellulärer Matrixanhäufung
WO1991010727A1 (en) * 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors

Also Published As

Publication number Publication date
JP2004043507A (ja) 2004-02-12
DE69228700T2 (de) 1999-09-09
ATE177644T1 (de) 1999-04-15
JP3854307B2 (ja) 2006-12-06
DK0616536T3 (da) 1999-10-11
NO942072D0 (no) 1994-06-03
AU7051896A (en) 1997-01-16
NO942072L (no) 1994-08-03
EP0616536A1 (de) 1994-09-28
AU3242993A (en) 1993-06-28
AU670770B2 (en) 1996-08-01
FI942622A (fi) 1994-07-27
CA2124591A1 (en) 1993-06-10
EP0616536B1 (de) 1999-03-17
JPH07504650A (ja) 1995-05-25
FI942622A0 (fi) 1994-06-03
WO1993010808A1 (en) 1993-06-10

Similar Documents

Publication Publication Date Title
DE69228700D1 (de) Verwendung von Decorin oder Biglycan zur Herstellung eines Medikaments für die Behandlung von Diabetes-bedingter Zustände
US5814094A (en) Iontopheretic system for stimulation of tissue healing and regeneration
JPS6429308A (en) Treatment of hyperhydrosis, psoriasis and wrinkle
Kanekura et al. Successful treatment of scleroderma with PUVA therapy
ATE372782T1 (de) Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin- abhängigen diabetes
ATE193541T1 (de) Insulinotropes hormon
Bertsch et al. Effect of mechanical stimulation on cell proliferation in mouse epidermis and on growth regulation by endogenous factors (chalones)
Okabe et al. Wound treatment using growth factors
Paunio et al. The effect of chlorhexidine gluconate on the formation of experimental granulation tissue.
Jeffcott et al. The treatment of horses with chronic back pain by resecting the summits of the impinging dorsal spinous processes
Ross et al. Comparison of the efficacy of silver-based antimicrobial burn dressings in a porcine model of burn wounds
Louis et al. A diabetogenic polypeptide from bovine adenohypophysis similar to that excreted in lipoatrophic diabetes
DE60005299T2 (de) Zubereitung für warzen
Katiyar et al. Pathology of inflammatory‐reparative response in punched wounds of the chicken skin
CN107050060A (zh) 治疗牛皮癣的外用药及药物组合物
Pierard et al. Phenytoin dependent fibrosis in polyfibromatosis syndrome
NZ513087A (en) Bactericidal/permability -increasing protein (BPI) for treating chronic heart disease
Salmon et al. Prolonged therapeutic effect of subcutaneously implanted crystals of ovarian hormone in women
DE3249215T1 (de) Verfahren zur herstellung von humanem (gamma)-interferon
KR890006657A (ko) 6-클로로-4-하이드록시-2-메틸-N-(2-피리딜)-2H-티에노(2,3-e)-1,2- 티아진-3 -카복스아미드 1,1- 디옥사이드의 엔올에테르 이의 제조방법 및 이의 용도
Rudenok et al. Innovative electrical unit for treatment of animals by direct electrochemical oxidation of blood
DE2336560C2 (de) Arzneimittel, enthaltend l-(2-Hydroxy-2-indanyl)-propylamin
Kurman et al. The proliferative response to epidermis of hairless mice to full thickness wounds.
Olenev et al. Method and Device for Treatment of Fungal Diseases of the Skin and Nails
DE2615654B2 (de) Salbenpräparat zur Intensivierung des WoIl- und Haarwachstums

Legal Events

Date Code Title Description
8364 No opposition during term of opposition